Multiplex Assay Kit for Insulin Like Growth Factor Binding Protein 7 (IGFBP7) ,etc. by FLIA (Flow Luminescence Immunoassay) 
FSTL2; IGFBP-7v; MAC25; PSF; TAF; IGFBP-rP1; MAC25 protein; Prostacyclin-stimulating factor; PGI2-stimulating factor; Tumor-derived adhesion factor
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 498.00 US$ 517.00 US$ 546.00 US$ 584.00 US$ 623.00 US$ 680.00 US$ 766.00 US$ 958.00
- Quantity
Overview
Properties
- Product No.LMB673Po
- Organism SpeciesSus scrofa; Porcine (Pig) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryMetabolic pathway
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Insulin Like Growth Factor Binding Protein 7 (IGFBP7) and the recovery rates were calculated by comparing the measured value to the expected amount of Insulin Like Growth Factor Binding Protein 7 (IGFBP7) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 78-89 | 82 |
| EDTA plasma(n=5) | 79-91 | 85 |
| heparin plasma(n=5) | 83-91 | 88 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Insulin Like Growth Factor Binding Protein 7 (IGFBP7) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Insulin Like Growth Factor Binding Protein 7 (IGFBP7) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Insulin Like Growth Factor Binding Protein 7 (IGFBP7) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 81-101% | 88-102% | 97-105% | 78-98% |
| EDTA plasma(n=5) | 96-105% | 98-105% | 83-97% | 90-104% |
| heparin plasma(n=5) | 96-104% | 96-103% | 82-95% | 83-92% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:IGFBP7) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
Test principle
Anti-Insulin Like Growth Factor Binding Protein 7 (IGFBP7) antibody was coated on the surface of magnetic beads, to make solid phase carrier. Standard or sample were added to the magnetic beads, respectively, in which Insulin Like Growth Factor Binding Protein 7 (IGFBP7) was bound to the antibody connected to the solid phase carrier, and then biotinylated anti-Insulin Like Growth Factor Binding Protein 7 (IGFBP7) antibodies were added. PE-labeled avidin was added. There is a positive correlation between the concentration of Insulin Like Growth Factor Binding Protein 7 (IGFBP7) in the sample and corresponding value of MFI (Median Fluorescence Intensity).
Giveaways
Increment services
Citations
- Role of IGFBP7 in Diabetic Nephropathy: TGF-β1 Induces IGFBP7 via Smad2/4 in Human Renal Proximal Tubular Epithelial CellsPubmed:26974954
- Role of IGFBP7 in Diabetic Nephropathy: TGF-β1 Induces IGFBP7 via Smad2/4 in Human Renal Proximal Tubular Epithelial Cells.pubmed:26974954
- Urine-Based Biomarkers for Alzheimer's Disease Identified Through Coupling Computational and Experimental MethodsPubmed:30040720
- IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung CancerPubmed: 30609749
- Insulin-like growth factor-binding protein 7 (IGFBP 7) as a new biomarker in coronary heart diseasePubmed: 30769262
- Altered insulin-like growth factor-2 signaling is associated with psychopathology and cognitive deficits in patients with schizophreniaPubmed: 32191705
- Discovery of novel biomarkers for atherosclerotic aortic aneurysm through proteomics-based assessment of disease progressionPubmed: 32286426
- SNORD116 and growth hormone therapy impact IGFBP7 in Prader¨CWilli syndrome34040195
- Biomarkers of persistent renal vulnerability after acute kidney injury recovery34707157
- IGFBP7 Concentration May Reflect Subclinical Myocardial Damage and Kidney Function in Patients with Stable Ischemic Heart DiseasePubmed:35204773
- Insulin-Like Growth Factor-Binding Protein 7 (IGFBP-7)—New Diagnostic and Prognostic Marker in Symptomatic Peripheral Arterial Disease?—Pilot StudyPubmed:35625639